Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Snorgaard, O.
Right arrow Articles by Binder, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snorgaard, O.
Right arrow Articles by Binder, C.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 15, Issue 8 1009-1013, Copyright © 1992 by American Diabetes Association


ARTICLES

Homogeneity in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr

O Snorgaard, LH Lassen and C Binder
Steno Memorial and Hvidore Hospital, Gentofte, Denmark.

OBJECTIVE--To study the natural history of beta-cell function from onset of IDDM to expected deterioration of insulin (C-peptide) secretion and to identify different patterns of decline, if any. RESEARCH DESIGN AND METHODS--A cohort of 204 consecutive newly diagnosed IDDM (clinical criteria) patients were followed prospectively for 7.4 yr (range 6-9 yr), measuring fasting C-peptide at onset, 1, 3, 6, 9, 12, and then every 6 mo until 106 wk (range 104-135 wk). Then, postprandial C-peptide was measured. RESULTS--Fasting C-peptide was 0.17 nM (range 0.11-0.25 nM) at onset followed by an annual increase rate of 0.16 nM/yr (range 0.06-0.48 nM/yr) to a peak of 0.28 nM (range 0.23-0.34 nM/yr) after 25 wk (range 12-39 wk). The subsequent annual decline rate of fasting C-peptide was 0.08 (0.05-0.12) and of postprandial C-peptide 0.03 nM/yr (range 0.02-0.06 nM/yr). None of these parameters showed bimodality in their distribution. However, some parameters were important. In men, fasting C-peptide at onset was lower, but the initial C-peptide increase rate was more pronounced compared to women. Furthermore, insulin-free remission was related to higher C-peptide levels throughout the study. C-peptide was higher during the 1st yr of diabetes in subjects greater than 30 yr of age at onset compared with younger diabetic patients. Stepwise multiple regression analysis showed that age, male sex, and fasting C-peptide at onset were of some predictive value for the C-peptide levels at 5 yr. However, simple group comparisons revealed no significant differences. CONCLUSIONS--No major heterogeneity exists in the pattern of decline of beta-cell function in IDDM, although small differences in pattern could be identified in both sexes, in different age-groups, and in relation to achieving insulin-free remission.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Diabetes CareHome page
J. M. Sosenko, J. P. Palmer, L. Rafkin-Mervis, J. P. Krischer, D. Cuthbertson, D. Matheson, and J. S. Skyler
Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1
Diabetes Care, November 1, 2008; 31(11): 2188 - 2192.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
N. A. Sherry, E. B. Tsai, and K. C. Herold
Natural History of {beta}-Cell Function in Type 1 Diabetes
Diabetes, December 1, 2005; 54(suppl_2): S32 - S39.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
G. Bruno, F. Cerutti, F. Merletti, P. Cavallo-Perin, E. Gandolfo, M. Rivetti, C. Runzo, S. Pinach, G. Pagano, and The Piedmont Study Group for Diabetes Epidemiology
Residual {beta}-Cell Function and Male/Female Ratio Are Higher in Incident Young Adults Than in Children: The registry of type 1 diabetes of the province of Turin, Italy, 1984-2000
Diabetes Care, February 1, 2005; 28(2): 312 - 317.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
C. Steele, W. A. Hagopian, S. Gitelman, U. Masharani, M. Cavaghan, K. I. Rother, D. Donaldson, D. M. Harlan, J. Bluestone, and K. C. Herold
Insulin Secretion in Type 1 Diabetes
Diabetes, February 1, 2004; 53(2): 426 - 433.
[Abstract] [Full Text]


Home page
DiabetesHome page
J. P. Palmer, G. A. Fleming, C. J. Greenbaum, K. C. Herold, L. D. Jansa, H. Kolb, J. M. Lachin, K. S. Polonsky, P. Pozzilli, J. S. Skyler, et al.
C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001
Diabetes, January 1, 2004; 53(1): 250 - 264.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Törn, M. Landin-Olsson, A. Lernmark, J. P. Palmer, H. J. Arnqvist, G. Blohmé, F. Lithner, B. Littorin, L. Nyström, B. Scherstén, et al.
Prognostic Factors for the Course of {beta} Cell Function in Autoimmune Diabetes
J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4619 - 4623.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1992 by the American Diabetes Association.